Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)
NCT ID: NCT01155427
Last Updated: 2010-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2009-05-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection
NCT00810524
Entecavir for Chronic Hepatitis B
NCT01323452
Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
NCT00704106
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
NCT01022801
Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients
NCT01356901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
entecavir
Patients initiating special antiviral treatments for CHB
No interventions assigned to this group
tenofovir
Patients initiating special antiviral treatments for CHB
No interventions assigned to this group
lamivudine
Patients initiating special antiviral treatments for CHB
No interventions assigned to this group
telbivudine
Patients initiating special antiviral treatments for CHB
No interventions assigned to this group
adefovir
Patients initiating special antiviral treatments for CHB
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 16 years or older
* No post-transplant patients
* RCT, non-randomized trials, prospective cohort studies, prospectively analyses case series published since 2003
* At least one arm of trial must include monotherapy with entecavir, lamivudine, tenofovir, adefovir, or telbivudine
* Study arms must include at least 10 patients
* Follow-up of at least 48 weeks
* Published results available in English language
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Study Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trials Disclosure
Investigator Inquiry form
For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI463-186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.